News and Community

Chief Medical Officer, Drug Administration, Genentech, Healthcare Technology, Kras G12c, Oncology

July 2, 2026

Genentech’s Divarasib Proves Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer